FASN and cancer: Reducing FASN activity retarded the malignancy of several gynaecological cancers, including breast [47,82,90,101,102,103,104,105], ovarian [48,51] and endometrial [100] cancer, in experimental studies using various FASN-inhibiting agents (e.g., C75, orlistat and cerulenin) and genetic perturbations, highlighting the crucial role of FASN in promoting the progression of these cancer types.